35 01/04/2023 31/03/2024 2024-03-31 false false false false false false false true false false true false false false false false false false No description of principal activities is disclosed 2023-04-01 Sage Accounts Production 23.0 - FRS102_2023 xbrli:pure xbrli:shares iso4217:GBP 03176158 2023-04-01 2024-03-31 03176158 2024-03-31 03176158 2023-03-31 03176158 2022-04-01 2023-03-31 03176158 2023-03-31 03176158 2022-03-31 03176158 bus:Director1 2023-04-01 2024-03-31 03176158 core:PatentsTrademarksLicencesConcessionsSimilar 2023-03-31 03176158 core:PatentsTrademarksLicencesConcessionsSimilar 2024-03-31 03176158 core:LandBuildings core:ShortLeaseholdAssets 2023-03-31 03176158 core:PlantMachinery 2023-03-31 03176158 core:LandBuildings core:ShortLeaseholdAssets 2024-03-31 03176158 core:PlantMachinery 2024-03-31 03176158 core:DeferredTaxation 2023-04-01 2024-03-31 03176158 core:WithinOneYear 2024-03-31 03176158 core:WithinOneYear 2023-03-31 03176158 core:LandBuildings core:ShortLeaseholdAssets 2023-04-01 2024-03-31 03176158 core:PlantMachinery 2023-04-01 2024-03-31 03176158 core:ShareCapital 2024-03-31 03176158 core:ShareCapital 2023-03-31 03176158 core:CapitalRedemptionReserve 2024-03-31 03176158 core:CapitalRedemptionReserve 2023-03-31 03176158 core:RetainedEarningsAccumulatedLosses 2024-03-31 03176158 core:RetainedEarningsAccumulatedLosses 2023-03-31 03176158 core:BetweenOneFiveYears 2024-03-31 03176158 core:BetweenOneFiveYears 2023-03-31 03176158 core:MoreThanFiveYears 2024-03-31 03176158 core:MoreThanFiveYears 2023-03-31 03176158 core:PatentsTrademarksLicencesConcessionsSimilar 2023-04-01 2024-03-31 03176158 core:PatentsTrademarksLicencesConcessionsSimilar 2023-03-31 03176158 core:CostValuation core:Non-currentFinancialInstruments 2023-03-31 03176158 core:AdditionsToInvestments core:Non-currentFinancialInstruments 2024-03-31 03176158 core:DisposalsRepaymentsInvestments core:Non-currentFinancialInstruments 2024-03-31 03176158 core:Non-currentFinancialInstruments core:RevaluationsIncreaseDecreaseInInvestments 2024-03-31 03176158 core:CostValuation core:Non-currentFinancialInstruments 2024-03-31 03176158 core:Non-currentFinancialInstruments 2024-03-31 03176158 core:Non-currentFinancialInstruments 2023-03-31 03176158 core:AcceleratedTaxDepreciationDeferredTax 2024-03-31 03176158 core:AcceleratedTaxDepreciationDeferredTax 2023-03-31 03176158 core:LandBuildings core:ShortLeaseholdAssets 2023-03-31 03176158 core:PlantMachinery 2023-03-31 03176158 core:DeferredTaxation 2023-03-31 03176158 core:DeferredTaxation 2024-03-31 03176158 bus:SmallEntities 2023-04-01 2024-03-31 03176158 bus:AuditExemptWithAccountantsReport 2023-04-01 2024-03-31 03176158 bus:SmallCompaniesRegimeForAccounts 2023-04-01 2024-03-31 03176158 bus:PrivateLimitedCompanyLtd 2023-04-01 2024-03-31 03176158 bus:FullAccounts 2023-04-01 2024-03-31 03176158 core:FinancialAssetsFairValueThroughProfitOrLossDeferredTax 2024-03-31 03176158 core:FinancialAssetsFairValueThroughProfitOrLossDeferredTax 2023-03-31
Company registration number: 03176158
HOME HEALTH (U.K.) LIMITED
Unaudited filleted financial statements
31 March 2024
HOME HEALTH (U.K.) LIMITED
Contents
Statement of financial position
Notes to the financial statements
HOME HEALTH (U.K.) LIMITED
Statement of financial position
31 March 2024
2024 2023
Note £ £ £ £
Fixed assets
Intangible assets 6 50 152
Tangible assets 7 26,512 32,841
Investments 8 741,423 725,291
_______ _______
767,985 758,284
Current assets
Stocks 2,610,716 2,570,492
Debtors 9 813,861 845,458
Cash at bank and in hand 1,032,632 1,181,534
_________ _________
4,457,209 4,597,484
Creditors: amounts falling due
within one year 10 ( 777,207) ( 909,146)
_______ _______
Net current assets 3,680,002 3,688,338
_________ _________
Total assets less current liabilities 4,447,987 4,446,622
Provisions for liabilities 11 ( 17,015) ( 7,722)
_________ _________
Net assets 4,430,972 4,438,900
_________ _________
Capital and reserves
Called up share capital 50 50
Capital redemption reserve 50 50
Profit and loss account 4,430,872 4,438,800
_________ _________
Shareholders funds 4,430,972 4,438,900
_________ _________
For the year ending 31 March 2024 the company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies.
Directors' responsibilities:
- The members have not required the company to obtain an audit of its financial statements for the year in question in accordance with section 476;
- The directors acknowledge their responsibilities for complying with the requirements of the Act with respect to accounting records and the preparation of financial statements.
These financial statements have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies' regime and in accordance with Section 1A of FRS 102 'The Financial Reporting Standard applicable in the UK and Republic of Ireland'.
In accordance with section 444 of the Companies Act 2006, the statement of comprehensive income has not been delivered.
These financial statements were approved by the board of directors and authorised for issue on 22 October 2024 , and are signed on behalf of the board by:
Mr J R Baxter
Director
Company registration number: 03176158
HOME HEALTH (U.K.) LIMITED
Notes to the financial statements
Year ended 31 March 2024
1. General information
The company is a private company limited by shares, registered in England and Wales. The address of the registered office is Chancellors House, Brampton Lane, London, NW4 4AB.
2. Statement of compliance
These financial statements have been prepared in compliance with the provisions of FRS 102, Section 1A, 'The Financial Reporting Standard applicable in the UK and Republic of Ireland'.
3. Accounting policies
Basis of preparation
The financial statements have been prepared on the historical cost basis, as modified by the revaluation of certain financial assets and liabilities measured at fair value through profit or loss. The financial statements are prepared in sterling, which is the functional currency of the entity.
Turnover
Turnover is measured at the fair value of the consideration received or receivable for goods supplied and services rendered, net of discounts and Value Added Tax.
Operating leases
Lease payments are recognised as an expense over the lease term on a straight-line basis. The aggregate benefit of lease incentives is recognised as a reduction to expense over the lease term, on a straight-line basis.
Intangible assets
Intangible assets are initially recorded at cost, and are subsequently stated at cost less accumulated amortisation and impairment losses. Trade marks are amortised over ten years on a straight line basis.
Tangible assets
Tangible assets are initially recorded at cost, and are subsequently stated at cost less any accumulated depreciation and impairment losses.
Depreciation
Depreciation is calculated so as to write off the cost or valuation of an asset, less its residual value, over the useful economic life of that asset as follows:
Leasehold improvements - Straight line over ten years (period of the lease)
Plant and machinery - 25% reducing balance
If there is an indication that there has been a significant change in depreciation rate, useful life or residual value of tangible assets, the depreciation is revised prospectively to reflect the new estimates.
Fixed asset investments
Listed investments are measured at fair value with changes in the fair value being recognised in profit or loss.
Stocks
Stocks are value at the lower of cost and net realisable value after making due allowance for obsolete and slow-moving stocks.
Defined contribution plans
Contributions to defined contribution plans are recognised as an expense in the period in which the related service is provided.
Foreign currencies
Transactions in foreign currencies are recorded in sterling at the exchange rate as at the date of the transaction. Monetary assets and liabilities denominated in foreign currencies are translated into sterling at the exchange rate prevailing at the reporting date. All exchange gains or losses are taken as profit or loss.
Financial instruments
The company only enters into basic financial instruments transactions that result in the recognition of financial assets and liabilities like trade and other accounts receivable and payable, amounts receivable or payable to related parties and other third parties. Debt instruments that are receivable or payable within one year, such as trade receivables and payables are measured, initially and subsequently, at the undiscounted amount of the cash or other consideration expected to be received or paid. Listed investments are measured at fair value with changes in the fair value being recognised in profit or loss.
Taxation
The taxation expense represents the aggregate amount of current and deferred tax recognised in the reporting period. Current tax is recognised on taxable profit for the current and past periods. Current tax is measured at the amounts of tax expected to pay or recover using the tax rates and laws that have been enacted or substantively enacted at the reporting date. Deferred tax is recognised in respect of all timing differences at the reporting date. Unrelieved tax losses and other deferred tax assets are recognised to the extent that it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits. Deferred tax is measured using the tax rates and laws that have been enacted or substantively enacted by the reporting date that are expected to apply to the reversal of the timing difference.
4. Employee numbers
The average number of persons employed by the company during the year amounted to 35 (2023: 34 ).
5. Income from other fixed asset investments
2024 2023
£ £
Dividends from listed investments 32,843 20,543
Gain/(Loss) on fair value adjustments-listed investments 43,496 (16,128)
_______ _______
76,339 4,415
_______ _______
6. Intangible assets
Trademarks Total
£ £
Cost
At 1 April 2023 and 31 March 2024 1,020 1,020
_______ _______
Amortisation
At 1 April 2023 868 868
Charge for the year 102 102
_______ _______
At 31 March 2024 970 970
_______ _______
Carrying amount
At 31 March 2024 50 50
_______ _______
At 31 March 2023 152 152
_______ _______
7. Tangible assets
Short leasehold property Plant and machinery Total
£ £ £
Cost
At 1 April 2023 50,417 37,443 87,860
Additions 5,846 973 6,819
Disposals - ( 7,846) ( 7,846)
_______ _______ _______
At 31 March 2024 56,263 30,570 86,833
_______ _______ _______
Depreciation
At 1 April 2023 34,927 20,092 55,019
Charge for the year 7,361 4,178 11,539
Disposals - ( 6,237) ( 6,237)
_______ _______ _______
At 31 March 2024 42,288 18,033 60,321
_______ _______ _______
Carrying amount
At 31 March 2024 13,975 12,537 26,512
_______ _______ _______
At 31 March 2023 15,490 17,351 32,841
_______ _______ _______
8. Investments
Loan to Home Health US, Inc. Listed Investments Total
£ £ £
Cost or valuation
At 1 April 2023 27,364 697,927 725,291
Additions 1,060 - 1,060
Disposals ( 28,125) - ( 28,125)
Revaluations ( 299) - ( 299)
Fair value adjustment - 43,496 43,496
_______ _______ _______
At 31 March 2024 - 741,423 741,423
_______ _______ _______
Impairment
At 1 April 2023 and 31 March 2024 - - -
_______ _______ _______
Carrying amount
At 31 March 2024 - 741,423 741,423
_______ _______ _______
At 31 March 2023 27,364 697,927 725,291
_______ _______ _______
Home Health US, Inc. is a wholly owned subsidiary of Home Health (U.K.) Limited.
9. Debtors
2024 2023
£ £
Trade debtors 628,516 640,405
Other debtors 185,345 205,053
_______ _______
813,861 845,458
_______ _______
10. Creditors: amounts falling due within one year
2024 2023
£ £
Trade creditors 356,205 465,039
Corporation tax 121,520 108,839
Social security and other taxes 267,231 264,814
Other creditors 32,251 70,454
_______ _______
777,207 909,146
_______ _______
11. Provisions
Deferred tax (note 12) Total
£ £
At 1 April 2023 7,722 7,722
Additions 9,293 9,293
_______ _______
At 31 March 2024 17,015 17,015
_______ _______
12. Deferred tax
The deferred tax included in the statement of financial position is as follows:
2024 2023
£ £
Included in provisions (note 11) 17,015 7,722
_______ _______
The deferred tax account consists of the tax effect of timing differences in respect of:
2024 2023
£ £
Accelerated capital allowances 6,628 8,210
Fair value adjustment of financial assets 10,387 ( 488)
_______ _______
17,015 7,722
_______ _______
13. Operating leases
The company as lessee
The total future minimum lease payments under non-cancellable operating leases are as follows:
£ £
Not later than 1 year 156,937 157,861
Later than 1 year and not later than 5 years 613,583 594,224
Later than 5 years 258,750 6,394
_________ _______
1,029,270 758,479
_________ _______